To determine whether the gold-aptamer-nanoconstructs were able to detect conserved target enteroviral nucleic acid sequence from simulated mucosal environments, cross sensitivity analyses were conducted by doping test samples with human genomic DNA prior to biosensor assessment. Cross sensitivity analyses were conducted at the detection limit of the conserved target enteroviral nucleic acid sequence of 1x10 -7 M. The efficacy of the gold-aptamer-nanoconstructs in the presence of human genomic DNA was conducted in the absence and presence of conserved target enteroviral nucleic acid sequence and assessed via the lateral flow assay.